Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: J Orthop Res. 2022 Nov 7;41(6):1162–1176. doi: 10.1002/jor.25470

Fig. 6. Met treatment inhibits HMGB1 translocation from the nuclei of the cells from aging tendon to the cytoplasm.

Fig. 6

Most of HMGB1 in aging tendon cells without Met treatment (0) are in cytoplasm (A, B), but Met treatment inhibits HMGB1 translocation in a concentration-dependent manner, with the difference between 100 and 500 μg/ml Met not being significantly different(C-H). Semi-quantification confirms the results (I). Western blot result further shows that both frHMGB1 and dsHMGB1 exist in aging tendon cells, but Met treatment decreases dsHMGB1 levels and increases frHMGB1 levels in aging tendon cells in an apparent concentration-dependent manner (J). White bars: 100 μm; Yellow bars: 25 μm, *p < 0.01 (treatment groups compared to without Met).